TRUE Private Wealth Advisors Grows Position in Eli Lilly and Company (NYSE:LLY)

TRUE Private Wealth Advisors raised its position in Eli Lilly and Company (NYSE:LLY) by 0.4% during the 4th quarter, Holdings Channel reports. The firm owned 9,088 shares of the company’s stock after acquiring an additional 32 shares during the quarter. Eli Lilly and Company comprises about 0.7% of TRUE Private Wealth Advisors’ holdings, making the stock its 27th biggest position. TRUE Private Wealth Advisors’ holdings in Eli Lilly and Company were worth $5,297,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Lipe & Dalton acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $26,000. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company during the third quarter valued at $27,000. Retirement Group LLC boosted its stake in shares of Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after acquiring an additional 35 shares during the last quarter. Cornerstone Planning Group LLC acquired a new stake in shares of Eli Lilly and Company during the second quarter valued at $33,000. Finally, Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter valued at $35,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research note on Friday, March 15th. Citigroup raised their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Barclays raised their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Morgan Stanley raised their price target on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Stock Down 0.5 %

LLY stock traded down $4.03 during midday trading on Wednesday, hitting $746.74. 2,569,799 shares of the company’s stock were exchanged, compared to its average volume of 2,215,511. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 12-month low of $367.35 and a 12-month high of $800.78. The firm has a 50 day moving average price of $763.51 and a 200-day moving average price of $657.01. The stock has a market capitalization of $709.52 billion, a price-to-earnings ratio of 128.75, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the previous year, the business earned $2.09 EPS. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. On average, analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at approximately $64,375,262,246.70. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.